As of November 6, 2026, the most recent 5%+ ownership report on Avidity Biosciences, Inc. names Avoro Capital Advisors LLC holding 5.54%. No bankruptcy or receivership appears in its SEC Form 8-K filings. This page cites 16 records in all (Schedule 13G/A, February 17, 2026).
Is this your company?
About to sign with, pay or invest in Avidity Biosciences, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Avidity Biosciences, Inc. a real, registered company?
- Avidity Biosciences, Inc. files with the SEC under CIK 1599901 (its SEC filings).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Avidity Biosciences, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Layoffs: 1 state WARN notice (latest 2026-10-29, San Diego CA, 40 employees).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Avoro Capital Advisors LLC (filed 2026-02-17).
Who are Avidity Biosciences, Inc.'s owners and officers?
Avidity Biosciences, Inc.: incorporated in Delaware; business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-05-15).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-03-19)
- : Executive Officer (Form D, 2024-03-19)
- : Executive Officer (Form D, 2024-03-19)
- : Executive Officer (Form D, 2024-03-19)
- : Executive Officer (Form D, 2024-03-19)
- : Director (Form D, 2024-03-19)
- : Director (Form D, 2024-03-19)
- : Director (Form D, 2024-03-19)
- : Director (Form D, 2024-03-19)
- : Director (Form D, 2024-03-19)
- : Director (Form D, 2024-03-19)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-05-15 | Ra Capital Management, L.P. | 0% |
| Schedule 13G/A, 2026-02-17 | Avoro Capital Advisors LLC | 5.54% |
| Schedule 13G/A, 2026-02-17 | T. Rowe Price Associates, Inc. | 0.1% |
| Schedule 13G/A, 2026-02-17 | Janus Henderson Group PLC | 4.6% |
| Schedule 13G/A, 2026-02-10 | Wellington Management Group LLP | 0.5% |
| Schedule 13G/A, 2025-12-05 | Janus Henderson Group PLC | 5.5% |
| Schedule 13G/A, 2025-11-14 | Janus Henderson Group PLC | 10.7% |
| Schedule 13G/A, 2025-11-14 | T. Rowe Price Associates, Inc. | 7.1% |
| Schedule 13G/A, 2025-11-14 | Ra Capital Management, L.P. | 5.9% |
| Schedule 13G/A, 2025-11-07 | Fmr LLC | 2.1% |
| Schedule 13G/A, 2025-11-05 | Fmr LLC | 15% |
| Schedule 13G/A, 2025-10-30 | The Vanguard Group | 9.57% |
Questions about who owns Avidity Biosciences, Inc.
Who owns Avidity Biosciences, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Avidity Biosciences, Inc.: The Vanguard Group (9.57%, Schedule 13G/A, filed 2025-10-30) and Avoro Capital Advisors LLC (5.54%, Schedule 13G/A, filed 2026-02-17).
Who are the largest shareholders of Avidity Biosciences, Inc.?
By the share each holder's latest filing reports, the largest holders of Avidity Biosciences, Inc. on this page are The Vanguard Group (9.57%) and Avoro Capital Advisors LLC (5.54%).
When did The Vanguard Group buy into Avidity Biosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from The Vanguard Group on this page is the Schedule 13G/A, filed 2025-10-30, reporting 9.57%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Avidity Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Avidity Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Avidity Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
How much has Avidity Biosciences, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-03-19 | $400.21M | $400.21M |
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-02-27).
Keep reading
More on Avidity Biosciences, Inc. and the records around it.
Avidity Biosciences, Inc. elsewhere on the record
- 5%+ stake filings May 2026
Companies that share a holder
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/avidity-biosciences